NCT06050863

Brief Summary

The current study is a prospective randomised split mouth study to evaluate the effect of Silk fibroin as drug delivery system while simultaneously assessing the efficacy of silk fibroin in comparison to chlorhexidine.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Nov 2023

Shorter than P25 for phase_1

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 16, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 22, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

November 1, 2023

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2024

Completed
Last Updated

September 22, 2023

Status Verified

September 1, 2023

Enrollment Period

7 months

First QC Date

September 16, 2023

Last Update Submit

September 16, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • Probing pocket Depth (PPD)

    measured using a UNC-15 probe (university of North Carolina-15 periodontal probe- Hu-Friedy, Chicago, IL, USA

    3 months

  • Relative attachment level (RAL)

    measured by placing the acrylic stent on the selected teeth using UNC-15 probe (university of North Carolina-15 periodontal probe- Hu-Friedy, Chicago, IL, USA)

    3 months

Secondary Outcomes (3)

  • Plaque Index

    3 months

  • Gingival index

    3 month

  • Modified Sulcus Bleeding Index

    3 months

Study Arms (3)

Group I - Silk Fibroin

EXPERIMENTAL

test group 1 is treated with silk fibroin

Biological: silk fibroin

Group II -Chlorhexidine

ACTIVE COMPARATOR

test group 2 is treated with chlorhexidine

Drug: Chlorhexidin

Group III - Combination of Fibroin and Chlorhexidine

EXPERIMENTAL

test group 3 is treated with combination of silk fibroin and chlorhexidine

Biological: combination of silk fibroin and chlorhexidine

Interventions

silk fibroinBIOLOGICAL

silk fibroin extracted from bombyx mori silk worm is processed in laboratory to form silk fibroin films

Group I - Silk Fibroin

chlorhexidine is used

Also known as: chlorhexidine
Group II -Chlorhexidine

combination of silk fibroin and chlorhexidine is used

Group III - Combination of Fibroin and Chlorhexidine

Eligibility Criteria

Age30 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Patient with age between 30-50 years.
  • Patients with stage I/ II with Grade A/ B periodontitis according to 2017 World workshop classification of periodontal disease will be considered.
  • Patients with localized periodontal pockets.
  • Patients willing to participate in the study.

You may not qualify if:

  • Patients with known systemic diseases.
  • Non complaint patients.
  • Patients who received any surgical or nonsurgical therapy 6 months before the start of the study.
  • Pregnant or lactating females.
  • Use of systemic antibiotics in the past 6 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Periodontal Pocket

Interventions

FibroinsChlorhexidine

Condition Hierarchy (Ancestors)

PeriodontitisPeriodontal DiseasesMouth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

SilkBiopolymersPolymersMacromolecular SubstancesArthropod ProteinsProteinsAmino Acids, Peptides, and ProteinsBiguanidesGuanidinesAmidinesOrganic Chemicals

Central Study Contacts

DR .Prabhuji MLV, MDS

CONTACT

DR. Aishwarya s, MDS

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 16, 2023

First Posted

September 22, 2023

Study Start

November 1, 2023

Primary Completion

June 1, 2024

Study Completion

July 1, 2024

Last Updated

September 22, 2023

Record last verified: 2023-09